H. Schirmer, P. Lunde, and K. Rasmussen, Prevalence of left ventricular hypertrophy in a general population; The Tromsø Study, Eur Heart J, vol.20, issue.6, pp.429-467, 1999.

P. Verdecchia, F. Angeli, R. Gattobigio, M. Sardone, S. Pede et al., Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects, Am J Hypertens, vol.19, pp.493-502, 2006.

D. A. Bluemke, R. A. Kronmal, J. Lima, K. Liu, J. Olson et al., The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study, J Am Coll Cardiol, vol.5, issue.25, pp.2148-55, 2008.

P. Verdecchia, C. Porcellati, G. Reboldi, R. Gattobigio, C. Borgioni et al., Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension, Circulation, vol.104, issue.17, pp.2039-2083, 2001.

D. Levy, R. J. Garrison, D. D. Savage, W. B. Kannel, and W. P. Castelli, Prognostic implications of echocardiographically

F. H. Messerli, Hypertension and sudden cardiac death, Am J Hypertens, vol.12, issue.S9, pp.181-188, 1999.

E. D. Frohlich, Left Ventricular Hypertrophy and Sudden Death, JACC, vol.32, issue.5, pp.1460-1462, 1998.

C. Cuspidi, S. Meani, C. Valerio, V. Fusi, C. Sala et al., Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives, J Hypertens, vol.24, pp.1671-1678, 2006.

A. U. Klingbeil, M. Schneider, P. Martus, F. H. Messerli, and R. E. Schmieder, A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension, Am J Med, vol.115, issue.1, pp.41-47, 2003.

B. Dahlöf, R. B. Devereux, S. E. Kjeldsen, J. S. Beevers, and G. Faire-u-de, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet, vol.359, pp.995-1003, 2002.

M. M. Ciulla, R. Paliotti, A. Esposito, J. Dìez, B. López et al., Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis: Results of a Randomized Trial, Circulation, vol.110, issue.5, pp.552-559, 2004.

S. D. Solomon, E. Appelbaum, W. J. Manning, A. Verma, T. Berglund et al., Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy, Circulation, vol.119, issue.4, pp.530-537, 2009.

P. Verdecchia, P. Sleight, G. Mancia, R. Fagard, B. Trimarco et al., Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease, Circulation, vol.120, issue.14, pp.1380-1389, 2009.

J. Mathew, P. Sleight, E. Lonn, D. Johnstone, J. Pogue et al., Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril, Circulation, vol.104, issue.14, pp.1615-1636, 2001.

S. D. Pierdomenico and F. Cuccurullo, Risk Reduction After Regression of Echocardiographic Left Ventricular Hypertrophy in Hypertension: A Meta-Analysis, Am J Hypertens, vol.23, issue.8, pp.876-81, 2010.

G. Du-cailar, J. Ribstein, and A. Mimran, Vieillissement et régression de l'hypertrophie cardiaque chez l'hypertendu, Rev Méd Interne, vol.19, pp.870-877, 1998.

P. Verdecchia, G. Schillaci, C. Borgioni, A. Ciucci, R. Gattobigio et al., Prognostic significance of serial changes in left ventricular mass in essential hypertension, Circulation, 1998.

E. Abergel and E. Tache, Lesnouveautés dans l'évaluation de l'hypertrophie ventriculaire gauche chez l'hypertendu par les indices électrocardiographiques, Cardiologue, vol.304, 1998.

O. J. Rider, N. Ntusi, S. C. Bull, R. Nethononda, V. Ferreira et al., Improvements in ECG accuracy for diagnosis of left ventricular hypertrophy in obesity, Heart, vol.102, pp.1566-72, 2016.

B. M. Goudie, R. I. Jarvis, P. T. Donnan, F. M. Sullivan, S. D. Pringle et al., Screening for left ventricular systolic dysfunction using GP-reported ECGs, Br J Gen Pract, vol.57, issue.536, pp.191-196, 2007.

V. Mor-avi, L. Sugeng, L. Weinert, P. Maceneaney, E. G. Caiani et al., Fast measurement of left ventricular mass with real-time three-dimensional echocardiography: comparison with magnetic resonance imaging, Circulation, vol.110, issue.13, pp.1814-1822, 2004.

A. Evangelista, V. Galuppo, J. Méndez, L. Evangelista, L. Arpal et al., Hand-held cardiac ultrasound screening performed by family doctors with remote expert support interpretation, Heart, vol.16, issue.5, pp.376-82, 2016.

R. Senior, G. Galasko, M. Hickman, P. Jeetley, and A. Lahiri, Community screening for left ventricular hypertrophy in patients with hypertension using hand-held echocardiography, J Am Soc Echocardiogr, vol.17, issue.1, pp.56-61, 2004.

R. M. Lang, M. Bierig, R. B. Devereux, F. A. Flachskampf, E. Foster et al., Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of, Cardiology. Journal of the American Society of Echocardiography, vol.27, issue.12, pp.1440-63, 2005.

J. Rodrigues, A. M. Amadu, A. G. Dastidar, G. V. Szantho, S. M. Lyen et al., Comprehensive characterisation of hypertensive heart disease left ventricular phenotypes. Heart, vol.102, pp.1671-1680, 2016.

R. B. Devereux and M. J. Roman, Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences, Hypertens Res, vol.22, issue.1, pp.1-9, 1999.

V. Palmieri, B. Dahlöf, V. Dequattro, and N. Sharpe,

G. Simone, Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement, J Am Coll Cardiol, vol.29, issue.5, pp.1625-1657, 1999.

N. Mansencal and A. Redheuil, Comment mesurer la masse ventriculaire gauche : échocadiographie et/ou IRM ? Revue mt cardio, vol.2, pp.249-54, 2006.

J. Sundström, L. Lind, J. Arnlöv, B. Zethelius, B. Andrén et al., Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men, Circulation, vol.103, pp.2346-51, 2001.

. Netgen, Hypertension : détection précoce des lésions des organes cibles. Revue Médicale Suisse, 2018.

A. Hornych and R. Asmar, Microalbuminurie et hypertension artérielle. La Presse médicale, vol.28, p.598, 1999.

P. Gosse, G. Papaioannou, P. Dubiez, S. Reuter, and P. Lemetayer, Hypertrophie ventriculaire gauche au cours de l'hypertension artérielle, EMC, 2008.

J. H. Mcgowan and J. G. Cleland, Reliability of reporting left ventricular systolic function by echocardiography: A systematic review of 3 methods, American Heart Journal. sept, vol.146, issue.3, pp.388-97, 2003.

. Serment-d'hippocrate,

, Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré(e) et méprisé(e) si j'y manque